Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP14012 in Erosive Gastroesophageal Reflux Disease
NCT03184324Phase 2Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fexuprazan in erosive gastroesophageal reflux disease (4 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Ratio of subjects who were completely cured of mucosal defects at 8 weeks. Started Aug 2017; status: completed.
02
Drugs
fexuprazan
03
Conditions
erosive gastroesophageal reflux disease
Beyond the preview
Go deeper on NCT03184324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184324.